Advanced search×

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.

Audio, Transactions of the IRE Profession... 35(3):119-30 (2009) PMID 19961450

DOI: 10.1111/j.1747-4477.2009.00213.x
Version: za2963e q8za4 q8zb3 q8zcc q8zda q8ze5 q8zf8 q8zgf

Similar articles you may find interesting…

  1. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

    Clin Cancer Res 11(23):8418-24 (2005) PMID 16322304

    Gefitinib monotherapy at 250 mg in recurrent and/or metastatic SCCHN seems to have less activity than was previously observed for 500 mg daily. A dose-response relationship may exist for this agent in SCCHN and grade of cutaneous toxicity attributable to gefitinib is a clinical predictor of better o...
  2. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

    J Oral Maxillofac Surg 62(5):8 (2004) PMID 15122554

    In view of the current trend of increasing and widespread use of chronic bisphosphonate therapy, our observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized potential complication. An early diagnosis might prevent or reduce...
  3. Positioning and mobility of the mandibular condyle after surgical correction of the asymmetric, prognathic mandible.

    Int J Adult Orthodon Orthognath Surg 5(1):29-34 (1990) PMID 2373910

    Following the extraoral vertical subcondylar osteotomy in the correction of the highly asymmetric and prognathic mandible, only insignificant radiographic changes were observed in the temporomandibular joint 12 months postoperatively. Slight morphologic alterations of the condylar seating were demon...